UA120060C2 - Виділене біспецифічне антитіло до cd123 (il3-r-alpha)хcd3 і його застосування - Google Patents

Виділене біспецифічне антитіло до cd123 (il3-r-alpha)хcd3 і його застосування

Info

Publication number
UA120060C2
UA120060C2 UAA201703200A UAA201703200A UA120060C2 UA 120060 C2 UA120060 C2 UA 120060C2 UA A201703200 A UAA201703200 A UA A201703200A UA A201703200 A UAA201703200 A UA A201703200A UA 120060 C2 UA120060 C2 UA 120060C2
Authority
UA
Ukraine
Prior art keywords
antibody
cancer
isolated
relates
binding agents
Prior art date
Application number
UAA201703200A
Other languages
English (en)
Inventor
Франсуа Ґоде
Франсуа Годэ
Рикардо Атар
Бенджамін К. Гарман
Бенджамин К. Гарман
Їнчже Лі
Инчже Ли
Цзіньцюань Ло
Цзиньцюань Ло
Ронан Макдейд
Ронан МакДэйд
Стивен К. Померантц
С'юзан Х. Тем
Сьюзан Х. Тэм
Алексій Тепляков
Алексий Тепляков
Джон Вілер
Джон Вилер
Шен-Дзюн У
Дженіфер Ф. Немет
Дженифер Ф. Немет
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of UA120060C2 publication Critical patent/UA120060C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Винахід стосується виділеного біспецифічного антитіла до CD123 (IL3-RR) x CD3 або його антигензв'язувального фрагмента, виділеного синтетичного полінуклеотиду, що кодує таке антитіло, виділеної клітини-хазяїна. Винахід також стосується фармацевтичної композиції, способу лікування суб’єкта, що має рак, способу інгібування росту або проліферації ракових клітин, способу перенаправлення Т-клітин до ракової клітини, що експресує CD123, та набору, що містить дане біоспецифічне антитіло.
UAA201703200A 2014-09-05 2015-09-03 Виділене біспецифічне антитіло до cd123 (il3-r-alpha)хcd3 і його застосування UA120060C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462046682P 2014-09-05 2014-09-05
PCT/US2015/048316 WO2016036937A1 (en) 2014-09-05 2015-09-03 Cd123 binding agents and uses thereof

Publications (1)

Publication Number Publication Date
UA120060C2 true UA120060C2 (uk) 2019-09-25

Family

ID=54150667

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201703200A UA120060C2 (uk) 2014-09-05 2015-09-03 Виділене біспецифічне антитіло до cd123 (il3-r-alpha)хcd3 і його застосування

Country Status (39)

Country Link
US (1) US9850310B2 (uk)
EP (2) EP3722315A1 (uk)
JP (2) JP6805130B2 (uk)
KR (1) KR102540192B1 (uk)
CN (1) CN107074956B (uk)
AR (1) AR101765A1 (uk)
AU (1) AU2015311931B2 (uk)
BR (1) BR112017004322A2 (uk)
CA (1) CA2959171C (uk)
CL (1) CL2017000515A1 (uk)
CO (1) CO2017002196A2 (uk)
CR (1) CR20170079A (uk)
CY (1) CY1122858T1 (uk)
DK (1) DK3189081T3 (uk)
EA (1) EA037647B1 (uk)
EC (1) ECSP17020812A (uk)
ES (1) ES2791249T3 (uk)
HR (1) HRP20200745T1 (uk)
HU (1) HUE048791T2 (uk)
IL (1) IL250770B (uk)
JO (1) JO3568B1 (uk)
LT (1) LT3189081T (uk)
MA (2) MA40609B1 (uk)
ME (1) ME03724B (uk)
MX (1) MX2017002891A (uk)
MY (1) MY186337A (uk)
NI (1) NI201700025A (uk)
PE (1) PE20171556A1 (uk)
PH (1) PH12017500472A1 (uk)
PL (1) PL3189081T3 (uk)
PT (1) PT3189081T (uk)
RS (1) RS60305B1 (uk)
SG (1) SG11201701599UA (uk)
SI (1) SI3189081T1 (uk)
TW (1) TWI693233B (uk)
UA (1) UA120060C2 (uk)
UY (1) UY36289A (uk)
WO (1) WO2016036937A1 (uk)
ZA (1) ZA201702369B (uk)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103097417B (zh) * 2010-04-20 2019-04-09 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
MA40801A1 (fr) 2015-01-23 2018-07-31 Sanofi Sa Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
US10100118B2 (en) 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
ES2889906T3 (es) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
JP7203497B2 (ja) 2015-06-29 2023-01-13 イミュノジェン・インコーポレーテッド 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体
EA038329B1 (ru) 2015-08-28 2021-08-10 Амьюникс Фармасьютикалз, Инк. Химерный полипептидный комплекс и способы его получения и применения
BR112018011781A2 (pt) 2015-12-14 2018-12-04 Macrogenics Inc molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
SG11201810331YA (en) 2016-05-20 2018-12-28 Harpoon Therapeutics Inc Single chain variable fragment cd3 binding proteins
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN109641047A (zh) 2016-05-20 2019-04-16 哈普恩治疗公司 单结构域血清白蛋白结合蛋白质
WO2017211731A1 (en) 2016-06-06 2017-12-14 F. Hoffmann-La Roche Ag Fusion proteins for ophthalmology with increased eye retention
WO2017214092A1 (en) 2016-06-07 2017-12-14 Macrogenics, Inc. Combination therapy
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
CN107840889A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗cd123抗体及其应用
AU2017331256A1 (en) 2016-09-21 2019-04-04 Aptevo Research And Development Llc CD123 binding proteins and related compositions and methods
MX2019006045A (es) 2016-11-23 2019-11-11 Harpoon Therapeutics Inc Proteinas triespecificas dirigidas a psma y metodos de uso.
EP3544997A4 (en) 2016-11-23 2020-07-01 Harpoon Therapeutics, Inc. PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN
CA3049689A1 (en) * 2017-02-06 2018-08-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for augmenting antibody mediated receptor signaling
WO2018156740A1 (en) 2017-02-24 2018-08-30 Macrogenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US20220127322A1 (en) * 2017-03-14 2022-04-28 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
JP7090347B2 (ja) 2017-05-12 2022-06-24 ハープーン セラピューティクス，インク． メソテリン結合タンパク質
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
US11472880B2 (en) 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
US20210061911A1 (en) * 2017-09-07 2021-03-04 Macrogenics, Inc. Dosing Regiments of Bi-Specific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies
CR20200195A (es) 2017-10-13 2020-08-14 Harpoon Therapeutics Inc Proteínas de unión a antigenos de maduraciòn de celulas b
KR102569133B1 (ko) 2017-10-13 2023-08-21 하푼 테라퓨틱스, 인크. 삼중특이적 단백질 및 사용 방법
JP7324749B2 (ja) * 2017-10-27 2023-08-10 ファイザー・インク Ｃｄ１２３に特異的な抗体および抗体－薬物コンジュゲートならびにその使用
CN111465618A (zh) 2017-12-12 2020-07-28 宏观基因有限公司 双特异性cd16-结合分子及其在疾病治疗中的用途
MX2020008489A (es) 2018-02-15 2020-09-25 Macrogenics Inc Dominios de union a cd3 variantes y su uso en terapias de combinacion para el tratamiento de enfermedades.
AU2019235523A1 (en) * 2018-03-14 2020-10-29 Novimmune Sa Anti-CD3 epsilon antibodies and methods of use thereof
CA3100157A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
WO2019224713A2 (en) 2018-05-24 2019-11-28 Janssen Biotech, Inc. Monospecific and multispecific anti-tmeff2 antibodies and there uses
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
KR20210015902A (ko) 2018-05-24 2021-02-10 얀센 바이오테크 인코포레이티드 Psma 결합제 및 이의 용도
CN113286817A (zh) 2018-09-25 2021-08-20 哈普恩治疗公司 Dll3结合蛋白及使用方法
AU2019362131A1 (en) * 2018-10-17 2021-05-27 Good T Cells, Inc. Binding molecule specific to Lrig-1 protein, and use thereof
MX2021010857A (es) * 2019-03-11 2021-12-15 Janssen Biotech Inc Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
CA3136888A1 (en) 2019-04-19 2020-10-22 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti- psma/cd3 antibody
CN113912697B (zh) * 2019-07-24 2023-05-30 暨南大学 靶向cd133的结合蛋白与应用
GB201912681D0 (en) 2019-09-04 2019-10-16 Eth Zuerich Bispecific binding agent that binds to cd117/c-kit and cd3
CN115768463A (zh) 2020-02-21 2023-03-07 哈普恩治疗公司 Flt3结合蛋白及使用方法
IL302351A (en) 2020-03-13 2023-06-01 Janssen Biotech Inc Materials and methods for binding SIGLEC-3/CD33
AU2021274151A1 (en) * 2020-05-19 2023-02-02 Janssen Biotech, Inc. Compositions comprising a T cell redirection therapeutic and a VLA-4 adhesion pathway inhibitor
US20220162314A1 (en) * 2020-10-23 2022-05-26 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
EP4271709A1 (en) 2020-12-31 2023-11-08 Sanofi Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
BR112023024209A2 (pt) * 2021-05-18 2024-01-30 Janssen Biotech Inc Composições que compreendem um agente terapêutico de redirecionamento de células t e um agente terapêutico anti-cd44
WO2023019121A2 (en) * 2021-08-09 2023-02-16 Merck Patent Gmbh Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines
WO2023138666A1 (en) * 2022-01-19 2023-07-27 Utc Therapeutics (Shanghai) Co., Ltd. Circular rna and use thereof
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1997024373A1 (en) 1995-12-29 1997-07-10 Medvet Science Pty. Limited Monoclonal antibody antagonists to haemopoietic growth factors
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
ATE294860T1 (de) 1997-09-16 2005-05-15 Egea Biosciences Llc Methoden zur kompletten chemischen synthese und zusammensetzung von genen und genomen
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
KR20080090406A (ko) 2005-11-28 2008-10-08 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
KR101732201B1 (ko) * 2009-04-27 2017-05-02 교와 핫꼬 기린 가부시키가이샤 혈액 종양 치료를 목적으로 하는 항ＩＬ－３Ｒα 항체
US9885711B2 (en) * 2009-09-25 2018-02-06 Xoma Technology Ltd. Screening methods
CN103097417B (zh) 2010-04-20 2019-04-09 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
NZ604510A (en) * 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
WO2013063702A1 (en) 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
PT2850106T (pt) 2012-05-18 2022-07-18 Aptevo Res & Development Llc Imunofusão biespecífica (bif) de scfv de ligação a cd123 e cd3

Also Published As

Publication number Publication date
CA2959171A1 (en) 2016-03-10
EP3189081B1 (en) 2020-02-19
SI3189081T1 (sl) 2020-07-31
JP2017529838A (ja) 2017-10-12
PT3189081T (pt) 2020-05-25
US9850310B2 (en) 2017-12-26
BR112017004322A2 (pt) 2017-12-05
PE20171556A1 (es) 2017-10-27
EA201790530A1 (ru) 2018-03-30
KR102540192B1 (ko) 2023-06-02
CL2017000515A1 (es) 2018-03-16
WO2016036937A1 (en) 2016-03-10
EA037647B1 (ru) 2021-04-27
DK3189081T3 (da) 2020-05-04
TW201625687A (zh) 2016-07-16
PL3189081T3 (pl) 2020-10-05
ES2791249T3 (es) 2020-11-03
RS60305B1 (sr) 2020-07-31
TWI693233B (zh) 2020-05-11
JP6805130B2 (ja) 2020-12-23
CA2959171C (en) 2023-11-14
US20160068605A1 (en) 2016-03-10
LT3189081T (lt) 2020-05-11
CN107074956B (zh) 2021-11-26
IL250770A0 (en) 2017-04-30
MA53145A (fr) 2021-05-19
MX2017002891A (es) 2017-10-11
AU2015311931B2 (en) 2020-09-03
EP3722315A1 (en) 2020-10-14
JO3568B1 (ar) 2020-07-05
EP3189081A1 (en) 2017-07-12
HRP20200745T1 (hr) 2020-08-07
AU2015311931A1 (en) 2017-03-16
UY36289A (es) 2016-04-01
AR101765A1 (es) 2017-01-11
ZA201702369B (en) 2018-12-19
JP2021050216A (ja) 2021-04-01
CN107074956A (zh) 2017-08-18
MA40609B1 (fr) 2020-05-29
ME03724B (me) 2021-01-20
CY1122858T1 (el) 2021-05-05
ECSP17020812A (es) 2018-07-31
SG11201701599UA (en) 2017-03-30
CR20170079A (es) 2017-04-27
NI201700025A (es) 2017-06-22
IL250770B (en) 2020-10-29
PH12017500472A1 (en) 2017-07-31
KR20170049554A (ko) 2017-05-10
HUE048791T2 (hu) 2020-09-28
MY186337A (en) 2021-07-13
CO2017002196A2 (es) 2017-07-28

Similar Documents

Publication Publication Date Title
UA120060C2 (uk) Виділене біспецифічне антитіло до cd123 (il3-r-alpha)хcd3 і його застосування
MX2018006973A (es) Anticuerpos anti-cd73 humanizados.
PH12018500241A1 (en) Antibody constructs for dll3 and cd3
PH12018500295A1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
PH12018500156A1 (en) Antibody constructs for egfrviii and cd3
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
EA201890382A1 (ru) Конструкции антител для cd70 и cd3
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
MY191649A (en) Antibodies to tigit
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
MX2021008367A (es) Constructos de anticuerpos para cdh19 y cd3.
EA201792193A1 (ru) Конструкции биспецифического антитела для cdh3 и cd3
MX2017014955A (es) Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
EA201890390A1 (ru) БИСПЕЦИФИЧЕСКИЕ КОНСТРУКТЫ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ EGFRvIII И CD3
EA201890383A8 (ru) Конструкции биспецифических антител, связывающиеся с мезотелином и кд3 (cd3)
EA201890337A1 (ru) Конструкции антитела к flt3 и cd3
EA201690443A1 (ru) Биспецифические моновалентные диатела, которые способны связываться с cd123 и cd3, и их применения
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
NZ757915A (en) Anti-par2 antibodies and uses thereof